Comparative potencies of contemporary generic vancomycin lot: In vitro assay results from nine products and a reference reagent-grade sample

Diagnostic Microbiology and Infectious Disease

Volumn 76, Issue 2, 2013, Pages 237-238

  Jones, Ronald N ^a   Watters, Amy A ^a   Flamm, Robert K ^a   Sader, Helio S ^a  

^a JMI LABORATORIES   (United States)

Author keywords

Generics; Potency; Validation; Vancomycin

Indexed keywords

GENERIC DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BIOLOGICAL ACTIVITY; BROTH DILUTION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG QUALITY; DRUG SCREENING; ENTEROCOCCUS FAECALIS; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; WILD TYPE;

ANTI-BACTERIAL AGENTS; DRUGS, GENERIC; ENTEROCOCCUS FAECALIS; MICROBIAL SENSITIVITY TESTS; REPRODUCIBILITY OF RESULTS; STAPHYLOCOCCUS AUREUS; UNITED STATES; VANCOMYCIN;

EID: 84877794970     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2013.01.008     Document Type: Article

References (17)

1. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard 2012, Clinical and Laboratory Standards Institute (CLSI), CLSI, Wayne, PA. ninth edition, (M07-A9).
2. Performance standards for antimicrobial susceptibility testing: 23rd informational supplement (M100-S23) 2013, Clinical and Laboratory Standards Institute (CLSI), CLSI, Wayne, PA.
3. Conte J.E. Comparative antibacterial activity of Vancocin and generic vancomycin. Antimicrob Agents Chemother 1987, 31:333-334.
4. Fujimura S., Watanabe A., Fuse K., Kikuchi T., Gomi K., Tokue Y. In vitro susceptibility of clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) to manufactured generic drugs compared with the brand vancomycin. Int J Antimicrob Agents 2008, 31:391-392.
5. Hadwiger M.E., Sommers C.D., Mans D.J., Patel V., Boyne M.T. Quality assessment of U.S. marketplace vancomycin for injection products using high-resolution liquid chromatography-mass spectrometry and potency assays. Antimicrob Agents Chemother 2012, 56:2824-2830.
6. Jones R.N., Fritsche T.R., Moet G.J. In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn, Wyeth) formulation. Diagn Microbiol Infect Dis 2008, 61:76-79.
7. Kaye D. Importation of foreign-made drugs: Are we getting what we expect? (editors comment). Clin Infect Dis 2008, 46:iii.
8. Moellering R.C. Vancomycin: a 50-year reassessment. Clin Infect Dis 2006, 42(Suppl. 1):S3-S4.
9. Moet G.J., Watters A.A., Sader H.S., Jones R.N. Expanded studies of piperacillin/tazobactam formulations: variations among branded product lots and assessment of 46 generic lots. Diagn Microbiol Infect Dis 2009, 65:319-322.
10. Nambiar S., Madurawe R.D., Zuk S.M., Khan S.R., Ellison C.D., Faustino P.J., et al. Product quality of parenteral vancomycin products in the United States. Antimicrob Agents Chemother 2012, 56:2819-2823.
11. Nation R.L., Sansom L.N. Bioequivalence requirements for generic products. Pharmacol Ther 1994, 62:41-55.
12. Rodriguez C.A., Agudelo M., Catano J.C., Zuluaga A.F., Vesga O. Potential therapeutic failure of generic vancomycin in a liver transplant patient with MRSA peritonitis and bacteremia. J Infect 2009, 59:277-280.
13. Rodriguez C.A., Agudelo M., Zuluaga A.F., Vesga O. Generic vancomycin enriches resistant subpopulations of Staphylococcus aureus after exposure in a neutropenic mouse thigh infection model. Antimicrob Agents Chemother 2012, 56:243-247.
14. Torres J.A., Tafur J.D., Briceno D.F., Pacheco R., Villegas M.V. Generic antibiotics are a risk factor for mortality in Acinetobacter baumanni infections in Colombian intensive care units (ICUs). 49th ICAAC, September 12-15, 2009. Abstr. K-312. San Francisco, CA 2009.
15. Vesga O., Agudelo M., Salazar B.E., Rodriguez C.A., Zuluaga A.F. Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator. Antimicrob Agents Chemother 2010, 54:3271-3279.
16. Wotterich U., Mutschler E. Quality of cefotaxime sodium preperations. Arzneimittelforschung 2005, 45:74-80.
17. Zuluaga A.F., Agudelo M., Rodriguez C.A., Vesga O. Application of microbiological assay to determine pharmaceutical equivalence of generic intravenous antibiotics. BMC Clin Pharmacol 2009, 9:1.